Belimumab for systemic lupus erythematosus
Review (6 RCTs; n=2917) found belimumab (US dose: 10 mg/kg) was probably associated with a clinically meaningful efficacy benefit but with no difference in health‐related quality of life or harm vs placebo at 52 weeks.
Source:
Cochrane Database of Systematic Reviews